2024
An extensive immunohistochemical analysis of 290 ovarian adult granulosa cell tumors with 29 markers
NEMEJCOVA, Kristyna, Adam SAFANDA, Michaela KENDALL BARTU, Romana MICHALKOVA, Marian SVAJDLER et. al.Základní údaje
Originální název
An extensive immunohistochemical analysis of 290 ovarian adult granulosa cell tumors with 29 markers
Autoři
NEMEJCOVA, Kristyna (203 Česká republika), Adam SAFANDA (203 Česká republika), Michaela KENDALL BARTU (203 Česká republika), Romana MICHALKOVA (203 Česká republika), Marian SVAJDLER (203 Česká republika), Tetiana SHATOKHINA (804 Ukrajina), Jan LACO (203 Česká republika), Radoslav MATEJ (203 Česká republika), Gabor MEHES (348 Maďarsko), Jana DROZENOVA (203 Česká republika), Jitka HAUSNEROVÁ (203 Česká republika, domácí), Zuzana SPURKOVA (203 Česká republika), Monika NÁLEŽINSKÁ (203 Česká republika, domácí) a Pavel DUNDR (203 Česká republika)
Vydání
Virchows Archiv, New York, Springer, 2024, 0945-6317
Další údaje
Jazyk
angličtina
Typ výsledku
Článek v odborném periodiku
Obor
30109 Pathology
Stát vydavatele
Spojené státy
Utajení
není předmětem státního či obchodního tajemství
Odkazy
Impakt faktor
Impact factor: 3.500 v roce 2022
Organizační jednotka
Lékařská fakulta
UT WoS
001251527400001
Klíčová slova anglicky
Ovarian tumors; Sex cord-stromal tumors; Granulosa cell tumors; Immunohistochemistry
Příznaky
Mezinárodní význam, Recenzováno
Změněno: 31. 10. 2024 15:02, Mgr. Tereza Miškechová
Anotace
V originále
The current knowledge about the immunohistochemical features of adult granulosa cell tumor (AGCT) is mostly limited to the "traditional" immunohistochemical markers of sex cord differentiation, such as inhibin, calretinin, FOXL2, SF1, and CD99. Knowledge about the immunohistochemical markers possibly used for predictive purpose is limited. In our study, we focused on the immunohistochemical examination of 290 cases of AGCT classified based on strict diagnostic criteria, including molecular testing. The antibodies used included 12 of the "diagnostic" antibodies already examined in previous studies, 10 antibodies whose expression has not yet been examined in AGCT, and 7 antibodies with possible predictive significance, including the expression of HER2, PD-L1, CTLA4, and 4 mismatch repair (MMR) proteins. The results of our study showed expression of FOXL2, SF1, CD99, inhibin A, calretinin, ER, PR, AR, CKAE1/3, and CAIX in 98%, 100%, 90%, 78%, 45%, 41%, 94%, 82%, 26%, and 9% of AGCT, respectively. GATA3, SATB2, napsin A, MUC4, TTF1, and CD44 were all negative. PTEN showed a loss of expression in 71% of cases and DPC4 in 4% of cases. The aberrant staining pattern (overexpression) of p53 was found in 1% (3/268) of cases, 2 primary tumors, and 1 recurrent case. Concerning the predictive markers, the results of our study showed that AGCT is microsatellite stable, do not express PD-L1, and are HER2 negative. The CTLA4 expression was found in almost 70% of AGCT tumor cells.
Návaznosti
LM2023033, projekt VaV |
|